ClinicalTrials.gg
CompletedNCT03162614Updated Oct 27, 2020Results posted

Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

A Phase 2 interventional study of RTS,S/AS01E and RTS,S/AS01B in Malaria, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-27.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 41 studies in Malaria by GlaxoSmithKline — 3 open to participants now, 3 under way, none of them phase 3. Malaria · GlaxoSmithKline.

Enrollment
24th of 38
154 · median 207
Started
2017
with 2 others
Phase 2
18 of 41
2 open now
Registered
34th of 41
by date

Among the 41 studies in Malaria by GlaxoSmithKline, this one is the 24th largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2017, is one of 18 in phase 2, and was the 34th registered.

Malaria

1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

3 of the 41 studies in Malaria by GlaxoSmithKline are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Malaria by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study is designed to evaluate efficacy, immunogenicity and safety of various dose schedules of GSK Biologicals' candidate malaria vaccines RTS,S/AS01B (adult formulation) and RTS,S/AS01E (pediatric formulation) in healthy malaria-naïve subjects aged 18-55 years. The purpose of this study is to investigate whether changes in dosing schedule are associated with increased or equivalent protection, and to evaluate the immune mechanisms associated with vaccine efficacy under varying dosing schedules.

Read the detailed description

Protocol Amendment 1 incorporated: additional blood sampling for assessment of parasitemia (polymerase chain reaction [PCR] testing); clarification that blood samples for both peripheral blood mononuclear cells (PBMC) and plasma will be collected for repository storage; revision of volume of whole blood samples to be taken for parasitemia assessment; clarification that urine pregnancy tests will be conducted for all females and not just those of childbearing potential; deletion of visit at Day 1 post day of challenge; clarification that RNA sequencing and not deep sequencing will be performed in this study.

Note that as a result of internal change in data standards terminology, the study data collected was converted to cDISC and the statistical analysis plan was amended accordingly. "Day 0" in the study design was replaced by "Day 1"; consequently, "Day n" was replaced by "Day n+1". Thus, the timeframes (Day 0, Day n) of Outcome Measures described in this study record are different to that denoted in the full protocol document posted.

03

Conditions studied

  • Malaria

Browse trials for

Keywords

  • healthy volunteers
  • Malaria
  • malaria vaccine
  • controlled human challenge
  • RTS,S/AS01
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written obtained from the subject prior to performing of any study specific procedure.
  • A male or female between, and including, 18 and 55 years of age at the time of enrolment.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Available to participate for the duration of the study.
  • Female subjects of non- may be enrolled in the study.

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or .
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test at enrolment, and
    • has agreed to continue adequate contraception during the entire treatment period and for two months after completion of the vaccination series and/or malaria challenge.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccines during the period starting 30 days before the first dose of study vaccines (Day -29 to Day 0), or planned use during the study period.
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
  • Chronic administration of or other immune-modifying drugs during the period starting six months prior to the first vaccine dose. For , this will mean prednisone ≥ 20 mg/day, or equivalent. Inhaled and topical steroids are allowed.
  • Administration of long-acting immune-modifying drugs at any time during the study period.
  • Chronic use of antibiotics with antimalarial effects.
  • Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting seven days before the first dose.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
  • Seropositive for surface antigen (HBsAg) or virus (HCV).
  • Documented -positive subject.
  • Previous vaccination against malaria.
  • History of malaria chemoprophylaxis within 60 days prior to vaccination.
  • Any history of malaria (for the vaccine groups).
  • Planned travel to malaria endemic areas during the study period.
  • History of splenectomy.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • Family history of congenital or hereditary immunodeficiency.
  • History of any reaction or likely to be exacerbated by any component of the vaccine.
  • History of anaphylaxis post-vaccination.
  • Hypersensitivity to latex.
  • History of any reaction or hypersensitivity likely to be exacerbated by chloroquine.
  • History of psoriasis and porphyria, which may be exacerbated after chloroquine treatment.
  • Current use of medications known to cause drug reactions to chloroquine.
  • History of severe reactions to mosquito bites.
  • Major congenital defects.
  • Serious chronic illness.
  • History of any neurological disorders or seizures.
  • Acute disease and/or fever at the time of enrolment. Fever is defined as temperature ≥ 37.5°C/99.5°F for oral, axillary or tympanic route, or ≥ 38.0°C/100.4°F for rectal route.

    • Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
  • Acute or chronic, pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
  • Any abnormal baseline laboratory screening tests: (ALT), aspartate aminotransferase (AST), creatinine, , count, total white blood cells (WBC), out of normal range as defined in the protocol.
  • Evidence of increased cardiovascular disease risk, "moderate" or "high", according to the National health and nutrition examination survey I criteria.
  • Hepatomegaly, right upper quadrant abdominal pain or tenderness.
  • Personal history of disease.
  • Administration of immunoglobulins and/or any blood products during the period starting three months before the first dose of study vaccine or planned administration during the study period.
  • Pregnant or lactating female.
  • History of chronic alcohol consumption and/or drug abuse.
  • Female planning to become pregnant or planning to discontinue precautions.
  • History of blood donation within 56 days preceding enrolment.
  • Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Active comparator
    AduFx Group

    Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and Month 1 and 1/5th of RTS,S/AS01B full dose at Month 7, and underwent sporozoite challenge.

    Biological: RTS,S/AS01B · Procedure: Sporozoite-infected mosquitoes challenge.

  • Experimental
    2PedFx Group

    Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E double dose at Month 0 and Month 1, and 1/5th of double dose RTS,S/AS01E at Month 7, and underwent sporozoite challenge.

    Biological: RTS,S/AS01E · Procedure: Sporozoite-infected mosquitoes challenge.

  • Experimental
    PedFx Group

    Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E full dose at Month 0 and Month 1, and 1/5th of RTS,S/AS01E full dose at Month 7, and underwent sporozoite challenge.

    Biological: RTS,S/AS01E · Procedure: Sporozoite-infected mosquitoes challenge.

  • Experimental
    Adu2Fx Group

    Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose at Month 1 and Month 7, and underwent sporozoite challenge.

    Biological: RTS,S/AS01B · Procedure: Sporozoite-infected mosquitoes challenge.

  • Active comparator
    Adu1Fx Group

    Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose administered at Month 7, and underwent sporozoite challenge.

    Biological: RTS,S/AS01B · Procedure: Sporozoite-infected mosquitoes challenge.

  • Other
    Control Group

    Healthy subjects, between, and including, 18 and 55 years of age, who did not receive any immunization but underwent sporozoite challenge.

    Procedure: Sporozoite-infected mosquitoes challenge.

Interventions

  • BiologicalRTS,S/AS01E

    Subjects will receive intramuscular injection of RTS,S/AS01E.

  • BiologicalRTS,S/AS01B

    Subjects will receive intramuscular injection of RTS,S/AS01B.

  • ProcedureSporozoite-infected mosquitoes challenge.

    Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the subjects. For each subject, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored. If required additional mosquitoes will be allowed to feed until a total of five infected mosquitoes with a minimum of 2+ salivary gland scores have fed. The challenge occurs approximately 90 days (three months) after the last vaccination. Subjects will be monitored during 28 days after having bitten by mosquitoes and when parasites are found in their blood, they will be treated with appropriate anti-malarial drugs.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With at Least One Occurrence of Plasmodium Falciparum (P. Falciparum) Parasitemia for Each Vaccination Schedule Versus Infectivity Controls

    Occurrence of P. falciparum parasitemia (defined by a positive blood slide) following sporozoite challenge. Post-challenge, parasitemia was determined by microscopy of Giemsa-stained thick blood films (smear). Microscopy was performed on thick smears using a validated standard operation procedure. For the analysis of proportion affected (relative risk), all subjects included in the analysis were considered at risk of infection and no censoring or elimination was applied for subjects not completing the entire protocol defined post challenge follow-up (Day 315 - 28 days post challenge).

    Time frame: Following sporozoite challenge starting 3 months after the last vaccine dose (Day 287) for up to 28 days post-challenge (Day 315).

Secondary outcomes

  1. Time to Onset of P. Falciparum Parasitemia After Sporozoite Challenge for Each Vaccination Schedule

    For the analyses of time to onset of parasitemia, time at risk started on first day of challenge. Time at risk was censored on Day 315 (28 days post challenge), drop-out date, start date of antimalarial treatment or date meeting an endpoint, whichever occurs first.

    Time frame: Following sporozoite challenge starting 3 months after the last vaccine dose (at Day 287) for up to 28 days post-challenge (at Day 315).

  2. Anti-Circumsporozoite (Anti-CS) Repeat Region Antibody Concentrations

    Anti-CS antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in Enzyme-linked immunosorbent assay Unit per milliliter (EU/mL). The cut-off for the assay was 1.9 EU/mL. The GMC calculations were performed by taking the anti-log of the mean of the log transformations (base 10). Antibody concentrations below the cut-off of the assay were given an arbitrary value of half the cut-off (=1.0) for the purpose of GMC calculation.

    Time frame: At Day 1, Day 59, Day 197, Day 227, Day 287, Day 315, and Day 377 for subjects from AduFx, 2PedFx, PedFx, and Adu2Fx Groups. At Day 1, Day 197, Day 227, Day 287, Day 315, and Day 377 for subjects from Adu1Fx Group

  3. Anti-Hepatitis B (Anti-HBs) Immunoglobulin G (IgG) Antibody Concentrations

    Anti-HBs IgG antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milli-International Unit per milliliter (mIU/ml). The cut-off for the assay was 6.2 mIU/mL.

    Time frame: At Day 1, Day 59, Day 197, Day 227, Day 287, Day 315, and Day 377 for subjects from AduFx, 2PedFx, PedFx, and Adu2Fx Groups. At Day 1, Day 197, Day 227, Day 287, Day 315, and Day 377 for subjects from Adu1Fx Group

  4. Number of Subjects With Any Solicited Local Symptoms

    Solicited local symptoms assessed are pain, redness and swelling. Any occurrence of symptom regardless of intensity grade. Any Redness or any Swelling symptom = any symptom greater than (\>) 0 millimeter (mm).

    Time frame: Within the 7-day period (Days 1-7) after dose 1, dose 2 (except for Adu1Fx Group) and dose 3.

  5. Number of Subjects With Any Solicited General Symptoms

    Solicited general symptoms assessed are fatigue, gastrointestinal symptoms, headache and fever. Any occurrence of symptom regardless of intensity grade. Fever was defined as temperature equal or greater than (≥) 37.5 degrees Celsius (°C) for oral route, axillary or tympanic route or 38.0°C for rectal route.

    Time frame: Within the 7-day period (Days 1-7) after dose 1, dose 2 (except for Adu1Fx Group) and dose 3.

  6. Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination

    An unsolicited adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited adverse event is any event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

    Time frame: Within the 30-day period (Days 1-30), after any vaccination (across doses)

  7. Number of Subjects With Any Unsolicited AEs After Challenge

    An adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Within the 30-day (Days 1-30) period post-challenge

  8. Number of Subjects With Any, Fatal or Related Serious Adverse Events (SAEs) After Each Vaccination

    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: Within the 30-day period (Days 1-30) after any vaccination (across doses)

  9. Number of Subjects With Any, Fatal or Related SAEs During the Whole Study Period

    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From Day 1 up to study conclusion (Day 377)

  10. Number of Subjects With Any AE and SAE Leading to Withdrawal From Further Vaccination

    An adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. SAEs include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From Day 1 up to study conclusion (Day 377)

  11. Number of Subjects With Potential Immune Mediated Diseases (pIMDs)

    Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

    Time frame: From Day 1 up to study conclusion (Day 377)

  12. Number of Subjects With Meningitis

    Meningitis is to be reported as an adverse event of specific interest and tabulated per study group.

    Time frame: From Day 1 up to study conclusion (Day 377)

  13. Number of Subjects With Abnormal Laboratory Values Gradings

    Biochemistry (Alanine Aminotransferase \[ALT\], Aspartate Aminotransferase \[AST\] and creatinine) and hematological (hemoglobin, platelets, White Blood Cells \[WBC\] decrease and WBC increase) laboratory values were presented according to toxicity grading scales (Grade 0 \[GR0\], Grade 1 \[GR1\], Grade 2 \[GR2\] Grade 3 \[GR3\]) and tabulated by group. Grading scale is taken from the \[FDA guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials (September 2007)\].

    Time frame: At Visit 1 Screening (Day -89 to Day 1), Day 36, Day 59, Day 204, Day 227, between Day 292 & Day 313, and Day 315 for each vaccinated subject.For Infectivity Control subjects at Visit 1b Screening (Day 231 to Day 287),between Day 292 & Day 313,and Day 315

  14. Number of Subjects With Any, Fatal or Related SAE, After Challenge

    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From day of challenge (Day 287) to the end of the challenge phase (Day 315)

07

Results

Posted Jul 24, 2019

Participant flow

Participant flow — Overall Study
MilestoneAduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx GroupControl Group
Started262626262624
Completed202122192124
Not completed654750
Withdrew: Lost to follow-up211120
Withdrew: Protocol violation010100
Withdrew: Withdrawal by subject211100
Withdrew: Missed vaccination, exclusion criteria222430

Outcome measures

PrimaryNumber of Subjects With at Least One Occurrence of Plasmodium Falciparum (P. Falciparum) Parasitemia for Each Vaccination Schedule Versus Infectivity Controls

Occurrence of P. falciparum parasitemia (defined by a positive blood slide) following sporozoite challenge. Post-challenge, parasitemia was determined by microscopy of Giemsa-stained thick blood films (smear). Microscopy was performed on thick smears using a validated standard operation procedure. For the analysis of proportion affected (relative risk), all subjects included in the analysis were considered at risk of infection and no censoring or elimination was applied for subjects not completing the entire protocol defined post challenge follow-up (Day 315 - 28 days post challenge).

Time frame:
Following sporozoite challenge starting 3 months after the last vaccine dose (Day 287) for up to 28 days post-challenge (Day 315).
Reported as:
Count of participants · Participants
Number of Subjects With at Least One Occurrence of Plasmodium Falciparum (P. Falciparum) Parasitemia for Each Vaccination Schedule Versus Infectivity Controls
ParticipantsAduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx GroupControl Group
Number of Subjects With at Least One Occurrence of Plasmodium Falciparum (P. Falciparum) Parasitemia for Each Vaccination Schedule Versus Infectivity Controls95891522
Statistical analysis
  • AduFx Group vs Control Group · Fisher Exact · p = <.001 · Vaccine efficacy rate: 55 · 95% CI 27 to 72
  • 2PedFx Group vs Control Group · Fisher Exact · p = <.001 · Vaccine efficacy rate: 76 · 95% CI 49 to 89
  • PedFx Group vs Control Group · Fisher Exact · p = <.001 · Vaccine efficacy rate: 64 · 95% CI 37 to 79
  • Adu2Fx Group vs Control Group · Fisher Exact · p = <.001 · Vaccine efficacy rate: 55 · 95% CI 27 to 72
  • Adu1Fx Group vs Control Group · Fisher Exact · p = 0.009 · Vaccine efficacy rate: 29 · 95% CI 6 to 46
SecondaryTime to Onset of P. Falciparum Parasitemia After Sporozoite Challenge for Each Vaccination Schedule

For the analyses of time to onset of parasitemia, time at risk started on first day of challenge. Time at risk was censored on Day 315 (28 days post challenge), drop-out date, start date of antimalarial treatment or date meeting an endpoint, whichever occurs first.

Time frame:
Following sporozoite challenge starting 3 months after the last vaccine dose (at Day 287) for up to 28 days post-challenge (at Day 315).
Reported as:
Mean · Days
Time to Onset of P. Falciparum Parasitemia After Sporozoite Challenge for Each Vaccination Schedule
DaysAduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx GroupControl Group
Time to Onset of P. Falciparum Parasitemia After Sporozoite Challenge for Each Vaccination Schedule14.8 ± 1.214.6 ± 1.114.3 ± 2.014.9 ± 2.114.2 ± 2.412.7 ± 1.9
SecondaryAnti-Circumsporozoite (Anti-CS) Repeat Region Antibody Concentrations

Anti-CS antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in Enzyme-linked immunosorbent assay Unit per milliliter (EU/mL). The cut-off for the assay was 1.9 EU/mL. The GMC calculations were performed by taking the anti-log of the mean of the log transformations (base 10). Antibody concentrations below the cut-off of the assay were given an arbitrary value of half the cut-off (=1.0) for the purpose of GMC calculation.

Time frame:
At Day 1, Day 59, Day 197, Day 227, Day 287, Day 315, and Day 377 for subjects from AduFx, 2PedFx, PedFx, and Adu2Fx Groups. At Day 1, Day 197, Day 227, Day 287, Day 315, and Day 377 for subjects from Adu1Fx Group
Reported as:
Geometric mean · EU/mL
Anti-Circumsporozoite (Anti-CS) Repeat Region Antibody Concentrations
EU/mLAduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx Group
At Day 11 (1.0 to 1.0)1 (1.0 to 1.0)1 (1.0 to 1.0)1 (1.0 to 1.0)1 (1.0 to 1.0)
At Day 59108.2 (70.1 to 167.0)107.8 (73.0 to 159.1)53.8 (39.0 to 74.1)61.7 (47.6 to 79.9)—
At Day 19730 (17.9 to 50.5)39.3 (23.8 to 64.8)15.1 (9.3 to 24.5)19.4 (13.2 to 28.5)3.8 (2.0 to 7.2)
At Day 22785.9 (50.8 to 145.5)79.8 (54.7 to 116.6)50.2 (35.5 to 70.9)64 (42.8 to 95.8)22.1 (12.0 to 40.8)
At Day 28761.4 (34.7 to 108.8)57.6 (38.2 to 87.1)34.4 (23.1 to 51.1)38.1 (20.8 to 69.9)12.3 (6.2 to 24.4)
At Day 31556.6 (32.5 to 98.4)51 (33.3 to 78.0)31.3 (21.2 to 46.3)44.1 (27.8 to 70.1)10.6 (5.2 to 21.5)
At Day 37743.7 (24.9 to 76.8)38.1 (24.3 to 59.8)25 (16.5 to 37.9)31.7 (19.6 to 51.3)9.5 (4.8 to 19.0)
SecondaryAnti-Hepatitis B (Anti-HBs) Immunoglobulin G (IgG) Antibody Concentrations

Anti-HBs IgG antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milli-International Unit per milliliter (mIU/ml). The cut-off for the assay was 6.2 mIU/mL.

Time frame:
At Day 1, Day 59, Day 197, Day 227, Day 287, Day 315, and Day 377 for subjects from AduFx, 2PedFx, PedFx, and Adu2Fx Groups. At Day 1, Day 197, Day 227, Day 287, Day 315, and Day 377 for subjects from Adu1Fx Group
Reported as:
Geometric mean · mIU/mL
Anti-Hepatitis B (Anti-HBs) Immunoglobulin G (IgG) Antibody Concentrations
mIU/mLAduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx Group
At Day 144.1 (15.6 to 124.3)68.8 (20.4 to 231.7)45.7 (15.2 to 137.5)21.8 (9.0 to 52.6)16 (6.5 to 39.6)
At Day 5942616.7 (12325.1 to 147356.7)28894.8 (8705.8 to 95903.3)26149.3 (8588.7 to 79615.2)14710.6 (3837.0 to 56398.8)—
At Day 19719369.3 (8325.5 to 45062.6)15358.8 (5971.2 to 39505.1)11269.1 (4892.1 to 25958.8)6846.7 (2273.5 to 20618.8)2031.7 (715.9 to 5766.4)
At Day 22745959.9 (27093.8 to 77962.8)30994.5 (15352.8 to 62572.4)28560.6 (15532.4 to 52516.4)26717 (12916.3 to 55263.3)35620.9 (22337.4 to 56803.7)
At Day 28736266.3 (21828.7 to 60252.9)20712.2 (10050.4 to 42684.5)19126.1 (9889.0 to 36991.5)13911.3 (4939.4 to 39179.9)16376.8 (9798.1 to 27372.8)
At Day 31533027.7 (19159.7 to 56933.4)18527.8 (8862.8 to 38732.5)17465.5 (8798.2 to 34671.2)16685 (8192.0 to 33982.9)12609.9 (7499.3 to 21203.5)
At Day 37727823 (15910.1 to 48655.8)15083.7 (6953.8 to 32718.4)13716 (6456.7 to 29136.9)11257.6 (5164.7 to 24538.5)10975.2 (5889.9 to 20451.3)
SecondaryNumber of Subjects With Any Solicited Local Symptoms

Solicited local symptoms assessed are pain, redness and swelling. Any occurrence of symptom regardless of intensity grade. Any Redness or any Swelling symptom = any symptom greater than (\>) 0 millimeter (mm).

Time frame:
Within the 7-day period (Days 1-7) after dose 1, dose 2 (except for Adu1Fx Group) and dose 3.
Reported as:
Count of participants · Participants
Number of Subjects With Any Solicited Local Symptoms
ParticipantsAduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx Group
Pain, dose 12321222219
Redness, dose 1811489
Swelling, dose 1512345
Pain, dose 220162012—
Redness, dose 281054—
Swelling, dose 25863—
Pain, dose 31112131615
Redness, dose 371010116
Swelling, dose 336533
SecondaryNumber of Subjects With Any Solicited General Symptoms

Solicited general symptoms assessed are fatigue, gastrointestinal symptoms, headache and fever. Any occurrence of symptom regardless of intensity grade. Fever was defined as temperature equal or greater than (≥) 37.5 degrees Celsius (°C) for oral route, axillary or tympanic route or 38.0°C for rectal route.

Time frame:
Within the 7-day period (Days 1-7) after dose 1, dose 2 (except for Adu1Fx Group) and dose 3.
Reported as:
Count of participants · Participants
Number of Subjects With Any Solicited General Symptoms
ParticipantsAduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx Group
Fatigue, dose 11314131011
Gastrointestinal symptoms, dose 158546
Headache, dose 1151410129
Fever, dose 136233
Fatigue, dose 21112106—
Gastrointestinal symptoms, dose 23673—
Headache, dose 21314116—
Fever, dose 26631—
Fatigue, dose 3468118
Gastrointestinal symptoms, dose 342605
Headache, dose 367699
Fever, dose 302020
SecondaryNumber of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination

An unsolicited adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited adverse event is any event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

Time frame:
Within the 30-day period (Days 1-30), after any vaccination (across doses)
Reported as:
Count of participants · Participants
Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination
ParticipantsAduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx Group
Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination1818151710
SecondaryNumber of Subjects With Any Unsolicited AEs After Challenge

An adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Within the 30-day (Days 1-30) period post-challenge
Reported as:
Count of participants · Participants
Number of Subjects With Any Unsolicited AEs After Challenge
ParticipantsAduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx GroupControl Group
Number of Subjects With Any Unsolicited AEs After Challenge000000
SecondaryNumber of Subjects With Any, Fatal or Related Serious Adverse Events (SAEs) After Each Vaccination

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
Within the 30-day period (Days 1-30) after any vaccination (across doses)
Reported as:
Count of participants · Participants
Number of Subjects With Any, Fatal or Related Serious Adverse Events (SAEs) After Each Vaccination
ParticipantsAduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx Group
Number of Subjects With Any, Fatal or Related Serious Adverse Events (SAEs) After Each Vaccination00000
SecondaryNumber of Subjects With Any, Fatal or Related SAEs During the Whole Study Period

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From Day 1 up to study conclusion (Day 377)
Reported as:
Count of participants · Participants
Number of Subjects With Any, Fatal or Related SAEs During the Whole Study Period
ParticipantsAduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx GroupControl Group
Number of Subjects With Any, Fatal or Related SAEs During the Whole Study Period000000
SecondaryNumber of Subjects With Any AE and SAE Leading to Withdrawal From Further Vaccination

An adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. SAEs include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From Day 1 up to study conclusion (Day 377)
Reported as:
Count of participants · Participants
Number of Subjects With Any AE and SAE Leading to Withdrawal From Further Vaccination
ParticipantsAduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx GroupControl Group
Number of Subjects With Any AE and SAE Leading to Withdrawal From Further Vaccination000000
SecondaryNumber of Subjects With Potential Immune Mediated Diseases (pIMDs)

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

Time frame:
From Day 1 up to study conclusion (Day 377)
Reported as:
Count of participants · Participants
Number of Subjects With Potential Immune Mediated Diseases (pIMDs)
ParticipantsAduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx GroupControl Group
Number of Subjects With Potential Immune Mediated Diseases (pIMDs)000000
SecondaryNumber of Subjects With Meningitis

Meningitis is to be reported as an adverse event of specific interest and tabulated per study group.

Time frame:
From Day 1 up to study conclusion (Day 377)
Reported as:
Count of participants · Participants
Number of Subjects With Meningitis
ParticipantsAduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx GroupControl Group
Number of Subjects With Meningitis000000
SecondaryNumber of Subjects With Abnormal Laboratory Values Gradings

Biochemistry (Alanine Aminotransferase \[ALT\], Aspartate Aminotransferase \[AST\] and creatinine) and hematological (hemoglobin, platelets, White Blood Cells \[WBC\] decrease and WBC increase) laboratory values were presented according to toxicity grading scales (Grade 0 \[GR0\], Grade 1 \[GR1\], Grade 2 \[GR2\] Grade 3 \[GR3\]) and tabulated by group. Grading scale is taken from the \[FDA guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials (September 2007)\].

Time frame:
At Visit 1 Screening (Day -89 to Day 1), Day 36, Day 59, Day 204, Day 227, between Day 292 & Day 313, and Day 315 for each vaccinated subject.For Infectivity Control subjects at Visit 1b Screening (Day 231 to Day 287),between Day 292 & Day 313,and Day 315
Reported as:
Count of participants · Participants
Number of Subjects With Abnormal Laboratory Values Gradings
ParticipantsAduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx GroupControl Group
Alanine Aminotransferase, SCR, Gr0252425252624
Alanine Aminotransferase, SCR, Gr1121000
Alanine Aminotransferase, SCR, Gr2000100
Alanine Aminotransferase, D36, Gr026242525——
Alanine Aminotransferase, D36, Gr10101——
Alanine Aminotransferase, D59, Gr026242424——
Alanine Aminotransferase, D59, Gr10112——
Alanine Aminotransferase, D204, Gr02122242420—
Alanine Aminotransferase, D204, Gr122013—
Alanine Aminotransferase, D227, Gr02220232322—
Alanine Aminotransferase, D227, Gr112111—
Alanine Aminotransferase, D227, Gr201000—
Alanine Aminotransferase, D292, Gr094781022
Alanine Aminotransferase, D292, Gr1001150
Alanine Aminotransferase, D292, Gr2010001
Alanine Aminotransferase, D315, Gr0162018181821
Alanine Aminotransferase, D315, Gr1314223
Alanine Aminotransferase, D315, Gr2100010
Aspartate Aminotransferase, SCR, Gr0262525252623
Aspartate Aminotransferase, SCR, Gr1011101
Aspartate Aminotransferase, D36, Gr026252426——
Aspartate Aminotransferase, D36, Gr10010——
Aspartate Aminotransferase, D59, Gr026242425——
Aspartate Aminotransferase, D59, Gr10111——
Aspartate Aminotransferase, D204, Gr02223242522—
Aspartate Aminotransferase, D204, Gr111001—
Aspartate Aminotransferase, D227, Gr02322232322—
Aspartate Aminotransferase, D227, Gr100101—
Aspartate Aminotransferase, D227, Gr201010—
Aspartate Aminotransferase, D292, Gr094791322
Aspartate Aminotransferase, D292, Gr1001020
Aspartate Aminotransferase, D292, Gr2000001
Aspartate Aminotransferase, D292, Gr3010000
Aspartate Aminotransferase, D315, Gr0202121182024
Aspartate Aminotransferase, D315, Gr1001210
Creatinine, SCR, Gr0262626252624
Creatinine, SCR, Gr1000100
Creatinine, D36, Gr025252526——
Creatinine, D36, Gr11000——
Creatinine, D59, Gr026252526——
Creatinine, D204, Gr02324242522—
Creatinine, D204, Gr100001—
Creatinine, D227, Gr02323242422—
Creatinine, D227, Gr100001—
Creatinine, D292, Gr095881522
Creatinine, D292, Gr1000100
Creatinine, D292, UNK000001
Creatinine, D315, Gr0202121202024
Creatinine, D315, Gr1001010
Hemoglobin, SCR, Gr0262626262623
Hemoglobin, SCR, Gr1000001
Hemoglobin, D36, Gr023242225——
Hemoglobin, D36, Gr13131——
Hemoglobin, D59, Gr025252425——
Hemoglobin, D59, Gr11011——
Hemoglobin, D204, Gr02024212523—
Hemoglobin, D204, Gr130300—
Hemoglobin, D227, Gr01923232323—
Hemoglobin, D227, Gr140110—
Hemoglobin, D292, Gr095881523
Hemoglobin, D292, Gr1000100
Hemoglobin, D315, Gr0162119182124
Hemoglobin, D315, Gr1403100
Hemoglobin, D315, Gr2000100
Platelets, SCR, Gr0262626262624
Platelets, D36, Gr026252526——
Platelets, D59, Gr026252526——
Platelets, D204, Gr02324242523—
Platelets, D227, Gr02323242423—
Platelets, D292, Gr095881519
Platelets, D292, Gr1000002
Platelets, D292, Gr2000100
Platelets, D292, Gr3000001
Platelets, D315, Gr0202122192122
Platelets, D315, Gr1000101
WBC Decrease, SCR, Gr0252526262624
WBC Decrease, SCR, Gr1110000
WBC Decrease, D36, Gr026242526——
WBC Decrease, D36, Gr10100——
WBC Decrease, D59, Gr026252426——
WBC Decrease, D59, Gr10010——
WBC Decrease, D204, Gr02324242523—
WBC Decrease, D227, Gr02323222423—
WBC Decrease, D227, Gr100200—
WBC Decrease, D292, Gr084681520
WBC Decrease, D292, Gr1112103
WBC Decrease, D315, Gr0202121202024
WBC Decrease, D315, Gr1001010
WBC Increase, SCR, Gr0252626252522
WBC Increase, SCR, Gr1100112
WBC Increase, D36, Gr025252523——
WBC Increase, D36, Gr11003——
WBC Increase, D59, Gr026252526——
WBC Increase, D204, Gr02324242321—
WBC Increase, D204, Gr100022—
WBC Increase, D227, Gr02223232423—
WBC Increase, D227, Gr110100—
WBC Increase, D292, Gr095891523
WBC Increase, D315, Gr0192022201924
WBC Increase, D315, Gr1000020
WBC Increase, D315, Gr2010000
WBC Increase, D315, Gr3100000
SecondaryNumber of Subjects With Any, Fatal or Related SAE, After Challenge

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From day of challenge (Day 287) to the end of the challenge phase (Day 315)
Reported as:
Count of participants · Participants
Number of Subjects With Any, Fatal or Related SAE, After Challenge
ParticipantsAduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx GroupControl Group
Number of Subjects With Any, Fatal or Related SAE, After Challenge000000

Adverse events

Collected over Solicited adverse events were reported during the 7-day follow-up period and unsolicited adverse events during the 30-day follow-up period after vaccination. Serious adverse events were reported during the whole study period (from Day 1 up to study conclusion at Day 377).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AduFx Group0/26 (0%)0/26 (0%)26/26 (100%)
2PedFx Group0/26 (0%)0/26 (0%)25/26 (96.2%)
PedFx Group0/26 (0%)0/26 (0%)23/26 (88.5%)
Adu2Fx Group0/26 (0%)0/26 (0%)25/26 (96.2%)
Adu1Fx Group0/26 (0%)0/26 (0%)24/26 (92.3%)
Control Group0/24 (0%)0/24 (0%)0/24 (0%)
Most frequent other events
Showing 10 of 68
Most frequent other events
EventAduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx GroupControl Group
Injection site painGeneral disorders23/2623/2623/2622/2620/260/24
FatigueGeneral disorders16/2620/2615/2613/2614/260/24
HeadacheNervous system disorders20/2620/2618/2616/2612/260/24
Injection site erythemaGeneral disorders14/2618/2612/2615/2612/260/24
Injection site swellingGeneral disorders9/2615/269/269/268/260/24
PyrexiaGeneral disorders8/2612/264/265/263/260/24
Gastrointestinal disorderGastrointestinal disorders9/2611/269/266/268/260/24
Upper respiratory tract infectionInfections and infestations1/263/263/267/262/260/24
ChillsGeneral disorders4/263/265/265/260/260/24
MalaiseGeneral disorders1/262/261/261/260/260/24

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx GroupControl GroupTotal
Mean31.7 ± 8.430.8 ± 9.632.0 ± 10.432.4 ± 10.932.2 ± 10.334.6 ± 11.932.3 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)AduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx GroupControl GroupTotal
Female1110124101057
Male15161422161497
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AduFx Group2PedFx GroupPedFx GroupAdu2Fx GroupAdu1Fx GroupControl GroupTotal
Asian1322109
Black Or African American861097848
Native Hawaiian Or Other Pacific Islander0000011
Other, Not Specified01224110
White17161213141486
08

Study locations

1 site
  • GSK Investigational Site
    Silver Spring, Maryland 20910, United States
09

References and documents

Publications

  • James E. Moon, Christian Ockenhouse, Jason A. Regules, Johan Vekemans, Cynthia Lee, Ilin Chuang, Magali Traskine, Erik Jongert, Karen Ivinson, Danielle Morelle, Jack L. Komisar, Marc Lievens, Martha Sedegah, Lindsey Garver, April K. Sikaffy, Norman C. Waters, William Ripley Ballou, Opokua Ofori-Anyinam for the RTS,S Malaria Vaccine Working Group. CLI_092_A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naïve Adults. J Infect Dis. 2020 Jul 20;jiaa421. doi: 10.1093/infdis/jiaa421. Online ahead of print.
  • Moon JE, Ockenhouse C, Regules JA, Vekemans J, Lee C, Chuang I, Traskine M, Jongert E, Ivinson K, Morelle D, Komisar JL, Lievens M, Sedegah M, Garver LS, Sikaffy AK, Waters NC, Ballou WR, Ofori-Anyinam O; RTS,S Malaria Vaccine Working Group. A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults. J Infect Dis. 2020 Oct 13;222(10):1681-1691. doi: 10.1093/infdis/jiaa421. PubMed 32687161 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Jul 2018, 13 months.

Results were first posted in Jul 2019, 1 year after primary completion.

Of 39 phase 2 interventional studies under Malaria, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2017
First posted
May 22, 2017
StartActual
May 24, 2017
Primary completionActual
Jul 9, 2018
CompletionActual
Sep 24, 2018
Results first posted
Jul 24, 2019
Last update
Oct 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03162614
Lead sponsor
GlaxoSmithKline
Collaborators
The PATH Malaria Vaccine Initiative (MVI)
Responsible party
Sponsor
First posted
May 22, 2017
Start date
May 24, 2017
Primary completion
Jul 9, 2018
Completion
Sep 24, 2018
Results posted
Jul 24, 2019
Last update
Oct 27, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion